In KEYNOTE-024, treatment naïve advanced NSCLC patients with PD-L1 tumor proportion score (TPS) ≥ 50% were randomized to pembrolizumab or platinum-based chemotherapy and demonstrated a durable survival benefit with pembrolizumab at 5 years (median OS 26.3 months versus 13.4 months, HR 0.62, 95% CI 0.48–0.81) [65]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.